Freshfields advises Helios Health on Eugin Group acquisition
Freshfields Bruckhaus Deringer has counselled Germany’s Helios Health on this deal with a value of €430 million
Freshfields Bruckhaus Deringer has advised Helios Health on its acquisition of the Eugin Group from NMC Health, through the purchase of a majority stake (and potentially 100%) in the Spanish company, Luarmia, S.L., and of 100% stake in NMC Eugin US Corporation, at a combined valuation of €430 million.
Helios Health is a German company, holding of the Fresenius-Helios private hospital and clinics business segment, which includes the business of Helios in Germany and the business of Quirónsalud in Spain and Latam. The acquisition will enable Helios to expand its international healthcare footprint in the IVF sector.
The transaction completion is subject to several regulatory approvals and is expected to happen in the first half of 2021.
Freshfields’ team advising on the deal was led in Spain by partner Javier Monzón (pictured) and in the US by partners John Fisher (Silicon Valley) and Paul Humphreys (New York), supported by lead associates Lucía Quiroga (Madrid) and David Chen (Silicon Valley), with the participation of Madrid associates Leticia Calbacho, Javier Sánchez-Valiente and Iciar Herrero. Tax advice was provided by partner Bosco Montejo supported by associate Álvaro Fernández, while Antitrust advice was provided by partner Álvaro Iza supported by senior associate Carmen Virgós and associate Álvaro Puig. Of Counsel Ignacio Borrego, supported by senior associate Ana Calvo and associate Miguel Ángel Calvo advised on the transaction regulatory aspects. Associates Arturo Dauffi (finance), Juan Pastor (employment) and Carolina Vergara (real estate) also assisted on the transaction.
Other offices involved included Washington, London and Rome. Freshfields has worked with local counsel in Brazil, Denmark, Sweden, Argentina, Colombia and Latvia.